Trastuzumab pamirtecan vs Tucatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Trastuzumab pamirtecan
Developed by BioNTech under a licence from DualityBio Inc.
NCT06265428 · Phase 3 · active, not recruiting
Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2027 · NCT06265428 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months.): NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. (met)
Result source: NCT06265428
Tucatinib
Marketed by Pfizer and partners
NCT03975647 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked, placebo-controlled trial of 466 patients, with progression-free survival as the primary endpoint. The primary comparison reached statistical significance in favor of tucatinib (hazard ratio 0.759, p=0.0163).
Next expected readout: December 2026 · NCT06016387 (registry estimate)
Reported efficacy
Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years): HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. (met)
Result source: NCT05132582
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tucatinib
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Available safety results
Tucatinib
| Dropout rate | 34.6% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultn/a: no completion milestone NCT02614794 · Phase 2 · combination |
|---|---|
| Discontinued due to AEs | — NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result— NCT02614794 · Phase 2 · combination |
| Serious AEs | 30.3% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result30.7% NCT02614794 · Phase 2 · combination |
| Most frequent reported AEs | nausea 65.4% (placebo 48.5%) diarrhoea 56.7% (placebo 26.6%) fatigue 48.9% (placebo 36.5%) NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultdiarrhoea 81.7% (placebo 53.8%) palmar-plantar erythrodysaesthesia syndrome 65.6% (placebo 53.3%) nausea 60.1% (placebo 44.2%) NCT02614794 · Phase 2 · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab pamirtecan's landscape · Tucatinib's landscape